**LAMPIRAN 1**

JBI Critical Appraisal Checklist for
quasi-experimental studies

Reviewer Wildan Regy Andraes

Author: Tunggul Sri Agus Setyaningsih dan Hesti Wahyuni Year: 2020

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Yes | No | Unclear | Not applicable |
| 1. Is it clear in the study what is the ‘cause’ and what is the ‘effect’ (i.e. there is no confusion about which variable comes first)?
 | □ | □ | □ | □ |
| 1. Were the participants included in any comparisons similar?
 | □ | □ | □ | □ |
| 1. Were the participants included in any comparisons receiving similar treatment/care, other than the exposure or intervention of interest?
 | □ | □ | □ | □ |
| 1. Was there a control group?
 | □ | □ | □ | □ |
| 1. Were there multiple measurements of the outcome both pre and post the intervention/exposure?
 | □ | □ | □ | □ |
| 1. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?
 | □ | □ | □ | □ |
| 1. Were the outcomes of participants included in any comparisons measured in the same way?
 | □ | □ | □ | □ |
| 1. Were outcomes measured in a reliable way?
 | □ | □ | □ | □ |
| 1. Was appropriate statistical analysis used?
 | □ | □ | □ | □ |

Overall appraisal: Include Exclude □ Seek further info □

**LAMPIRAN 2**

JBI Critical Appraisal Checklist for
randomized Controlled trials

Reviewer Wildan Regy Andreas Date 2021

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Yes | No | Unclear | NA |
| 1. Was true randomization used for assignment of participants to treatment groups?
 | □  | □ | □ | □ |
| 1. Was allocation to treatment groups concealed?
 | □ | □ | □ | □ |
| 1. Were treatment groups similar at the baseline?
 | □ | □ | □ | □ |
| 1. Were participants blind to treatment assignment?
 | □ | □ | □  | □ |
| 1. Were those delivering treatment blind to treatment assignment?
 | □ | □  | □ | □ |
| 1. Were outcomes assessors blind to treatment assignment?
 | □ | □ | □ | □ |
| 1. Were treatment groups treated identically other than the intervention of interest?
 | □ | □ | □  | □ |
| 1. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?
 | □  | □ | □ | □ |
| 1. Were participants analyzed in the groups to which they were randomized?
 | □ | □  | □ | □ |
| 1. Were outcomes measured in the same way for treatment groups?
 | □ | □ | □ | □ |
| 1. Were outcomes measured in a reliable way?
 | □  | □ | □ | □ |
| 1. Was appropriate statistical analysis used?
 | □  | □ | □ | □ |
| 1. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?
 | □ | □  | □ | □ |

Author: Ozge Karakaya Suzan et al., Year 2020 Record Number \_\_\_\_\_\_\_\_\_\_

Overall appraisal: Include □ Exclude □ Seek further info □

**LAMPIRAN 3**

JBI Critical Appraisal Checklist for
randomized Controlled trials

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Yes | No | Unclear | NA |
| 1. Was true randomization used for assignment of participants to treatment groups?
 | □ | □ | □ | □ |
| 1. Was allocation to treatment groups concealed?
 | □ | □ | □ | □ |
| 1. Were treatment groups similar at the baseline?
 | □ | □ | □ | □ |
| 1. Were participants blind to treatment assignment?
 | □ | □ | □ | □ |
| 1. Were those delivering treatment blind to treatment assignment?
 | □ | □  | □ | □ |
| 1. Were outcomes assessors blind to treatment assignment?
 | □ | □ | □ | □ |
| 1. Were treatment groups treated identically other than the intervention of interest?
 | □ | □ | □ | □ |
| 1. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?
 | □ | □ | □ | □ |
| 1. Were participants analyzed in the groups to which they were randomized?
 | □ | □ | □ | □ |
| 1. Were outcomes measured in the same way for treatment groups?
 | □ | □ | □ | □ |
| 1. Were outcomes measured in a reliable way?
 | □ | □ | □ | □ |
| 1. Was appropriate statistical analysis used?
 | □ | □ | □ | □ |
| 1. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?
 | □ | □ | □ | □ |

Reviewer: Wildan Regy Andreas Date

Author: Muhammet Bulut et al., Year: 2020

Overall appraisal: Include □ Exclude □ Seek further info □

# LAMPIRAN 4

JBI Critical Appraisal Checklist for
randomized Controlled trials

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Yes | No | Unclear | NA |
| 1. Was true randomization used for assignment of participants to treatment groups?
 | □ | □ | □ | □ |
| 1. Was allocation to treatment groups concealed?
 | □ | □ | □ | □ |
| 1. Were treatment groups similar at the baseline?
 | □ | □ | □ | □ |
| 1. Were participants blind to treatment assignment?
 | □ | □ | □ | □ |
| 1. Were those delivering treatment blind to treatment assignment?
 | □ | □  | □ | □ |
| 1. Were outcomes assessors blind to treatment assignment?
 | □ | □ | □ | □ |
| 1. Were treatment groups treated identically other than the intervention of interest?
 | □ | □ | □ | □ |
| 1. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?
 | □ | □ | □ | □ |
| 1. Were participants analyzed in the groups to which they were randomized?
 | □ | □ | □ | □ |
| 1. Were outcomes measured in the same way for treatment groups?
 | □ | □ | □ | □ |
| 1. Were outcomes measured in a reliable way?
 | □ | □ | □ | □ |
| 1. Was appropriate statistical analysis used?
 | □ | □ | □ | □ |
| 1. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?
 | □ | □ | □ | □ |

Reviewer Wildan Regy Andreas Date 2021

Author Hassannia et al., Year: 2021

Overall appraisal: Include □ Exclude □ Seek further info □

**LAMPIRAN 5**

JBI Critical Appraisal Checklist for
randomized Controlled trials

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Yes | No | Unclear | NA |
| 1. Was true randomization used for assignment of participants to treatment groups?
 | □ | □ | □ | □ |
| 1. Was allocation to treatment groups concealed?
 | □ | □ | □ | □ |
| 1. Were treatment groups similar at the baseline?
 | □ | □ | □ | □ |
| 1. Were participants blind to treatment assignment?
 | □ | □ | □ | □ |
| 1. Were those delivering treatment blind to treatment assignment?
 | □ | □  | □ | □ |
| 1. Were outcomes assessors blind to treatment assignment?
 | □ | □ | □ | □ |
| 1. Were treatment groups treated identically other than the intervention of interest?
 | □ | □ | □ | □ |
| 1. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?
 | □ | □ | □ | □ |
| 1. Were participants analyzed in the groups to which they were randomized?
 | □ | □ | □ | □ |
| 1. Were outcomes measured in the same way for treatment groups?
 | □ | □ | □ | □ |
| 1. Were outcomes measured in a reliable way?
 | □ | □ | □ | □ |
| 1. Was appropriate statistical analysis used?
 | □ | □ | □ | □ |
| 1. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?
 | □ | □ | □ | □ |

Reviewer Wildan Regy Andreas Date 2021

Author: Esra Tural Buyuk et al., Year: 2021

Overall appraisal: Include □ Exclude □ Seek further info □